{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T22:13:24Z","timestamp":1766268804253,"version":"3.37.0"},"reference-count":34,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate demographic and clinical characteristics, treatment patterns, and quality of life in patients with locally advanced or metastatic urothelial carcinoma in Asia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were drawn from the Adelphi Real World Metastatic Urothelial Carcinoma Disease Specific Programme\u2122, a cross\u2010sectional survey of medical oncologists\/urologists and their adult patients in Saudi Arabia, South Korea, Taiwan, and Turkey. Exploratory patient\u2010reported outcomes included the EQ\u20105D visual analog scale, European Organisation for Research and Treatment of Cancer Quality of Life of Patient Questionnaire global health, and Brief Pain Inventory. Analyses were descriptive.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 175 physicians reported data for 988 patients. Mean (standard deviation) patient age was 66.3 (10.8) years, 77% were men, and 82% had bladder tumors at diagnosis. Of patients receiving first\u2010 (<jats:italic>n<\/jats:italic>\u2009=\u2009988), second\u2010 (<jats:italic>n<\/jats:italic>\u2009=\u2009290), and third\u2010line (<jats:italic>n<\/jats:italic>\u2009=\u200987) treatments, 81%, 35%, and 59% received chemotherapy, respectively, and 17%, 63%, and 34% received programmed cell death protein 1\/ligand 1 inhibitors, respectively. Patient\u2010reported (<jats:italic>n<\/jats:italic>\u2009=\u2009319) mean (standard deviation) EQ\u20105D visual analog scale score was 51.8 (15.6), European Organisation for Research and Treatment of Cancer Quality of Life of Patient Questionnaire global health status score was 44.6 (19.9), and Brief Pain Inventory score was 6.5 (1.9; <jats:italic>n<\/jats:italic>\u2009=\u2009315).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The most common first\u2010 and second\u2010line treatments for locally advanced or metastatic urothelial carcinoma were chemotherapy and programmed cell death protein 1\/ligand inhibitors, respectively. At third line, 10% of patients received best supportive care alone, underscoring an unmet need for effective third\u2010line treatment options. Patients in all regions reported quality\u2010of\u2010life impairment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/iju.15497","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T14:55:33Z","timestamp":1716562533000},"page":"933-943","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real\u2010world treatment patterns and quality of life among patients with locally advanced or metastatic urothelial carcinoma living in Saudi Arabia, South Korea, Taiwan, and Turkey"],"prefix":"10.1111","volume":"31","author":[{"given":"Li\u2010Jen","family":"Cheng","sequence":"first","affiliation":[{"name":"Medical Affairs Astellas Pharma Singapore Pte, Ltd.  Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Kim","sequence":"additional","affiliation":[{"name":"Biostatistics Astellas Pharma Global Development  Northbrook Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apurba","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Medical Affairs Astellas Pharma Singapore Pte, Ltd.  Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Milloy","sequence":"additional","affiliation":[{"name":"Adelphi Real World  Bollington UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mia","family":"Unsworth","sequence":"additional","affiliation":[{"name":"Adelphi Real World  Bollington UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Ng","sequence":"additional","affiliation":[{"name":"Medical Affairs Astellas Pharma Singapore Pte, Ltd.  Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21551"},{"key":"e_1_2_15_3_1","first-page":"15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala K","year":"2020","journal-title":"Med Sci (Basel)"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.012"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.12.032"},{"key":"e_1_2_15_7_1","unstructured":"WHO.Estimated number of prevalent cases (1\u2010year) as a proportion in 2020 bladder both sexes all ages.2020.https:\/\/gco.iarc.fr\/today\/online\u2010analysis\u2010map?v=2020&mode=population&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=30&type=2&statistic=5&prevalence=1&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=10&group_cancer=1&include_nmsc=0&include_nmsc_other=1&projection=natural\u2010earth&color_palette=default&map_scale=quantile&map_nb_colors=5&continent=4&show_ranking=0&rotate=%255B10%252C0%255D"},{"volume-title":"Cancer registry annual report","year":"2020","author":"Taiwan Health Promotion Administration","key":"e_1_2_15_8_1"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0072"},{"key":"e_1_2_15_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.757"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3571"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30040277"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.5534"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562872221147760"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1313"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.106"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309863"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002297"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.20285"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.11.014"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.23162"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29100599"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802457040"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352"},{"key":"e_1_2_15_25_1","unstructured":"EuroQoL Research Foundation.EQ\u20105D\u20105L User Guide.2021.https:\/\/euroqol.org\/publications\/user\u2010guides\/"},{"volume-title":"The EORTC QLQ\u2010C30 scoring manual","year":"2001","author":"Fayers P","key":"e_1_2_15_26_1"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-018-0088-8"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphys.2015.07.001"},{"key":"e_1_2_15_29_1","unstructured":"ScottNW FayersPM AaronsonNK BottomleyA deGraeffA GroenvoldM et\u00a0al.EORTC QLQ\u2010C30 Reference Values.2008. [cited February 29 2024].https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/reference_values_manual2008.pdf"},{"key":"e_1_2_15_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.001"},{"key":"e_1_2_15_31_1","doi-asserted-by":"crossref","unstructured":"PuenteJ.Real\u2010world treatment patterns survival outcomes and health care resource utilization (HCRU) for locally advanced or metastatic urothelial carcinoma (la\/mUC) in Spain [poster number 463].American Society of Clinical Oncology Genitourinary Cancers Symposium;2023;San Francisco CA.","DOI":"10.1200\/JCO.2023.41.6_suppl.463"},{"key":"e_1_2_15_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.01.001"},{"key":"e_1_2_15_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2022.08.002"},{"key":"e_1_2_15_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.05.001"},{"key":"e_1_2_15_35_1","doi-asserted-by":"publisher","DOI":"10.1159\/000526962"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.15497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T06:50:39Z","timestamp":1738911039000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.15497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1111\/iju.15497"],"URL":"https:\/\/doi.org\/10.1111\/iju.15497","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"type":"print","value":"0919-8172"},{"type":"electronic","value":"1442-2042"}],"subject":[],"published":{"date-parts":[[2024,5,24]]},"assertion":[{"value":"2023-11-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}